Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-02-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if treatment with medications that reduce the male
hormone level in the participant's body for a few months before surgery can shrink prostate
cancer as much as possible, which might reduce the chances of the cancer coming back in the
future. These treatments include a hormone injection given monthly or every three months and
the study drugs, which include abiraterone acetate, prednisone, and apalutamide.
These medications are being used in combination with surgery and maybe radiotherapy because
studies have shown that any single approach on its own is not sufficient to control or get
rid of the cancer especially if they have high risk or aggressive features. The researchers
hope to learn if combining the study drugs with surgery and radiation will get rid of the
cancer from participants' prostates and reduce their prostate-specific antigen (PSA) to an
undetectable level.